These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15567298)

  • 1. Formulation development of inhalation powders for FK888 using the E-haler to improve the inhalation performance at a high dose, and its absorption in healthy volunteers.
    Nakate T; Yoshida H; Ohike A; Tokunaga Y; Ibuki R; Kawashima Y
    Eur J Pharm Biopharm; 2005 Jan; 59(1):25-33. PubMed ID: 15567298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler and its absorption in healthy volunteers.
    Nakate T; Yoshida H; Ohike A; Tokunaga Y; Ibuki R; Kawashima Y
    J Control Release; 2004 May; 97(1):19-29. PubMed ID: 15147801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):72-80. PubMed ID: 16442248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates.
    Feddah MR; Brown KF; Gipps EM; Davies NM
    J Pharm Pharm Sci; 2000; 3(3):318-24. PubMed ID: 11177650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the lung absorption of FK224 inhaled from a pressurized metered dose inhaler and a dry powder inhaler by healthy volunteers.
    Nakate T; Yoshida H; Ohike A; Tokunaga Y; Ibuki R; Kawashima Y
    Eur J Pharm Biopharm; 2003 Nov; 56(3):319-25. PubMed ID: 14602173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
    Munzel U; Marschall K; Fyrnys B; Wedel M
    Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation.
    Chege JK; Chrystyn H
    Respir Med; 2000 Jan; 94(1):51-6. PubMed ID: 10714479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methacholine dry powder inhaler as a new tool for bronchial challenge test.
    Colombo G; Terzano C; Colombo P; Petroianni A; Ricci A; Buttini F
    Int J Pharm; 2008 Mar; 352(1-2):165-71. PubMed ID: 18055141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug/lactose co-micronization by jet milling to improve aerosolization properties of a powder for inhalation.
    Giry K; Péan JM; Giraud L; Marsas S; Rolland H; Wüthrich P
    Int J Pharm; 2006 Sep; 321(1-2):162-6. PubMed ID: 16797150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS; Lau R
    Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
    Minne A; Boireau H; Horta MJ; Vanbever R
    Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.
    Bhavna ; Ahmad FJ; Mittal G; Jain GK; Malhotra G; Khar RK; Bhatnagar A
    Eur J Pharm Biopharm; 2009 Feb; 71(2):282-91. PubMed ID: 18984050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation.
    Sebti T; Pilcer G; Van Gansbeke B; Goldman S; Michils A; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2006 Aug; 64(1):26-32. PubMed ID: 16697169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
    Srichana T; Martin GP; Marriott C
    Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.
    Kawabata Y; Aoki Y; Matsui T; Yamamoto K; Sato H; Onoue S; Yamada S
    Eur J Pharm Biopharm; 2011 Jan; 77(1):178-81. PubMed ID: 21081161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimisation of spray-drying process variables for dry powder inhalation (DPI) formulations of corticosteroid/cyclodextrin inclusion complexes.
    Cabral-Marques H; Almeida R
    Eur J Pharm Biopharm; 2009 Sep; 73(1):121-9. PubMed ID: 19446024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of HPMC Inhalation-Grade Capsules and Their Effect on Aerosol Performance Using Budesonide and Rifampicin DPI Formulations.
    Ding L; Brunaugh AD; Thakkar R; Lee C; Zhao QJ; Kalafat J; Maniruzzaman M; Smyth HDC
    AAPS PharmSciTech; 2022 Jan; 23(1):52. PubMed ID: 35018574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.